TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT04427904

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bupivacaine 0.5% with 1:200 000 epinephrine
Description: Bupivacaine 0.5% with 1:200 000 epinephrine. Total volume 10mL for local infiltration before neck incision.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Lidocaine 2% with 1:100 000 epinephrine
Description: Lidocaine 2% with 1:100 000 epinephrine. Total volume 10mL for local infiltration before neck incision.
Study: NCT06355414

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Psilocybin
Description: Drug administration under supportive conditions
Study: NCT06192043

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Behavioral Psychoeducational Intervention
Description: Psychoeducational Program would be used as an intervention strategy for individuals with smoking cessation to provide understanding and insight to the participants about the problem. Furthermore, this program would deal with interventions like motivation, cognitive conceptualization, coping skills and training, craving management, and relapse prevention among individuals with smoking cessation
Study: NCT04931524

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: carbon-14-[14C]-ANG-3777
Description: Arms assigned to this intervention will receive 240 mg, IV and not more than 5.2 MBq, Fasted
Study: NCT06355414

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Methylphenidate
Description: Drug administration under supportive conditions
Study: NCT05126810

Intervention type: OTHER
Intervention: Questionnaire Administration
Description: Complete questionnaire
Study: NCT04723472

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cefuroxime containing bismuth quadruple treatment
Description: Cefuroxime containing bismuth quadruple treatment:~Rabeprazole 20mg bid po, Colloidal Bismuth Pectin 200mg bid po, Cefuroxime 500mg bid po, Metronidazole 400mg tid po Treatment duration is 14 days.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Classic bismuth quadruple treatment
Description: Classic bismuth quadruple treatment:~Rabeprazole 20mg bid po, Colloidal Bismuth Pectin 200mg bid po, Tetracycline 500mg qid po, Metronidazole 400mg tid po Treatment duration is 14 days.
Study: NCT05995678

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: STEP-Home-SP
Description: This group will meet for \~1.5 hours/week for 12 weeks. The core skills of Emotional Regulation (ER) and Problem Solving (PS) are introduced and then integrated throughout all Veteran-specific content modules for practice and repetition for 12 weeks. Attention training augments ER and PS skills and is interspersed throughout the group and individual sessions. Additional 30-minute individual skills building and goal setting sessions occur up to 6 times based on individual Veteran needs. STEP-Home staff will work in pairs to run workshops per established protocols. Workshops will be conducted via VA approved video telehealth.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Transition Assistance Program
Description: Provides training, skills, and information to help transitioning service members and their families prepare for the military to civilian transition. Each service member works with a TAP counselor to identify needs and post transition goals to build an Individual Transition Plan, in addition to TAP core curriculum courses.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Transition Assistance Program
Description: Provides training, skills, and information to help transitioning service members and their families prepare for the military to civilian transition. Each service member works with a TAP counselor to identify needs and post transition goals to build an Individual Transition Plan, in addition to TAP core curriculum courses.
Study: NCT06482112

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Efinopegdutide
Description: SC injections in dose-escalation regimens potentially including doses of 2 mg, 4 mg, 7 mg, and 10 mg in all arms and 15 mg in the Efinopegdutide Q2W 15 mg arm

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Efinopegdutide
Description: SC injections in dose-escalation regimens potentially including doses of 2 mg, 4 mg, 7 mg, and 10 mg in all arms and 15 mg in the Efinopegdutide Q2W 15 mg arm

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Efinopegdutide
Description: SC injections in dose-escalation regimens potentially including doses of 2 mg, 4 mg, 7 mg, and 10 mg in all arms and 15 mg in the Efinopegdutide Q2W 15 mg arm
Study: NCT05952518

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Sprint PNS system
Description: Temporary electrical stimulation of the medial nerve with implanted wires and wearable stimulator

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Radiofrequency Ablation
Description: Thermal ablation of the medial nerve
Study: NCT05651789

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Carvedilol
Description: Carvedilol is started at a dose of 6.25mg/d, and titrated to a maximum dose of 12.5mg/d. Doses are increased 3 days later. Avoid systolic blood pressure \<90 mmHg.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Propranolol
Description: Propranolol is started at a dose of 20 mg/d and the dose will be increased by 10 mg twice a day steps every 2-3 days until the target (heart rate: 55\~60 bpm) or to a maximum dose of 160 mg/d. Systolic arterial pressure is not less than 90 mm Hg and heart rate is not less than 50 bpm.
Study: NCT05054478

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Daratumumab
Description: Daratumumab added to induction, first consolidation and second consolidation
Study: NCT05995678

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: VA Solid Start
Description: VA Solid Start includes a series of outreach calls and emails to all Veterans at 90-, 180-, and 365-days post service separation. Callers follow a standard script to describe services available through VA and provide contact information for desired services.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: VA Solid Start
Description: VA Solid Start includes a series of outreach calls and emails to all Veterans at 90-, 180-, and 365-days post service separation. Callers follow a standard script to describe services available through VA and provide contact information for desired services.
Study: NCT05562128

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Active forest therapy
Description: Participants take part in a two-hour active clinical forest therapy in Berlin-Wannsee on two days (with a break day in between). In this setting, a trained clinical forest therapist teaches exercises on the perception of nature and the connection between nature and health.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Passive forest therapy
Description: Participants take part in a two-hour passive clinical forest therapy in Berlin-Wannsee over two days (with a break day in between). In this setting, a trained clinical forest therapist will guide participants to various locations in the forest where participants can stay and let nature have its effect on them.
Study: NCT05118503

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Customized education
Description: Half of subjects will receive access to a customized app that will include brief educational videos that have been selected for each patient based on their medical history. These videos will address stroke etiology, underlying risk factors, and stroke prevention medications.
Study: NCT06355791

Intervention type: DEVICE
Group type: OTHER
Intervention: Minuteman G5
Description: The Minuteman G5 MIS Fusion Plate consists of spinous process plates and surgical instruments. Implants are made of Titanium alloy
Study: NCT05187130

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Mindfulness
Description: 60 patients in the mindfulness-based breathing and music therapy group were divided into subgroups of 5 participants each. Each 6-person group started by having participants complete the pretest State Anxiety Inventory, Beck Depression Inventory, and Psychological Well-Being Scale via Survey Monkey. Mindfulness-based breathing and music therapy was applied to each patient group in approximately 45-minute sessions per day. At the end of the session, participants re-filled the posttest State Anxiety Inventory, Work-Related Tension Scale, and Psychological Well-Being Scale. A total of 3 sessions were completed with an interval of two days.
Study: NCT05118503

Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: Standard of care discharge education
Description: Half of subjects will be randomized to receive typical discharge education, per the institutional guidelines for standard of care education for stroke patients.
Study: NCT04949477

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Dexmedetomidine
Description: the patient will receive intranasal dexmedetomidine at a dose of 1 μg/kg to the patient 45 min. before the procedure.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: paracetamol
Description: the patient will receive paracetamol orally \[Rx paracetamol 250 mg/ml\] at a dose of 20 mg/kg given to the patient 45 min before the procedure by drinking.
Study: NCT05893810

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Mupirocin Ointment
Description: Patients in the intervention arm will receive a decolonization regimen, consisting of intranasal mupirocin ointment to be applied twice daily to the nares
Study: NCT05255848

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Unfractionated heparin
Description: Patients will be given the same standard of care treatment plus nebulized heparin 5000IU every 8 hours started 24 hours after randomization, using a compressed air nebulizer, and will be continued for one week. In case of any complication, if the attending physician feels it necessary intervention treatment will be stopped
Study: NCT06132594

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Conventional arthrocentesis followed by I-PRF injection
Description: An auriculotemporal nerve block using Mebacaine 0.5% was administered near the mandible's neck. The patient sat at a 45° angle with their head turned. The posterior entry point was 10 mm from the midtragus and 2 mm below the line, while the anterior entry point was marked 20 mm from the midtragus and 10 mm below the line. A biting block kept the mouth open. 2-3 ml of Ringer lactate was injected with an 18-gauge needle to enlarge the joint space. A second needle allowed the solution to flow freely. After lavaging the joint, 1 ml of I-PRF was injected into the upper joint space. Jaw manipulation was done to address adhesions and improve disc mobility.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: 3d surgical guided Arthrocentesis followed by I-PRF injection
Description: Patients underwent arthrocentesis with Ringer lactate, followed by I-PRF injection in the TMJ's superior space using a CT-planned 3D-printed guide. Positioned at a 45° angle, patients were comfortably seated, and disinfection was performed. The patient-specific guide, fitting over maxillary teeth and the face, was employed unilaterally or bilaterally with a biting block for mouth opening maintenance. An 18-gauge needle administered 2-3 ml of Ringer lactate, widening the joint space, followed by a second needle allowing free solution flow (80-90 ml) to flush the superior joint space. Post-arthrocentesis, 1 ml of I-PRF was injected. To enhance joint mobility and free the disc, gentle manipulation of the lower jaw was performed after removing the needles and guide.
Study: NCT05081518

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lu AG06466
Description: Lu AG06466 - capsule

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lu AG06466
Description: Lu AG06466 - capsule

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Placebo - capsule
Study: NCT06033794

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Fluorescence laparoscopic system
Description: Intraoperative fluorescence imaging was performed using the DPM-ENDOCAM-03 and DPM-LIGHT-03 fluorescence imaging system (manufactured by Digital Precision Medicine Technology Co., Ltd., Zhuhai, China). This system provides original fluorescence mode, color mode, and fusion mode, allowing real-time quantitative analysis of the fluorescence signals.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Fluorescence laparoscopic system
Description: Intraoperative fluorescence imaging was performed using the DPM-ENDOCAM-03 and DPM-LIGHT-03 fluorescence imaging system (manufactured by Digital Precision Medicine Technology Co., Ltd., Zhuhai, China). This system provides original fluorescence mode, color mode, and fusion mode, allowing real-time quantitative analysis of the fluorescence signals.
Study: NCT04951999

Intervention type: OTHER
Group type: OTHER
Intervention: Blood sampling
Description: For 10 visits (out of the 12 of the protocol), \~40 ml of blood is sampled for research purposes in addition to care sampling.
Study: NCT00692081

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Social competence training
Description: 8 group sessions multi-modal social competence training, 2-4 hours each, 2 trainers, 6-10 participants

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Special vocational training
Description: as provided in German special centres for vocational training
Study: NCT05480085

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: School-based extracurricular intervention focusing on screen media use and time spent with friends
Description: The intervention includes the following components:~1. Within each class parents will engage in two meetings combining education and parent-to-parent communication about 1) the children's leisure time activities, and 2) family and class screen time culture. Parents will engage in a short exercise focusing on screen media dilemmas conducted by the teacher in the beginning of 4th grade.~2. Children will engage in school hour workshops focusing on the class culture related to screen media use and leisure time activities.~3. Afterschool club personal will engage in mini actions learning program consisting of three workshops aimed to increase participation rate in the afterschool club.~4. Local stakeholders, e.g., parents, school- and afterschool club personal and others relevant to children's leisure time (e.g., sports clubs) will engage in workshops to adjust the predetermined intervention components (1-3 above) to fit their local context and to develop a local action plan.
Study: NCT04849455

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 0.2% ropivacaine local anesthetic continuous erector spinae plane block
Description: Treatment- continuous erector spinae block catheter followed by an infusion of ropivacaine 0.2% at 10ml automatic set bolus per 60 minute with 2ml/hr continuous infusion (12mls/hr total per catheter)

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: 0.2% ropivacaine local anesthetic superficially taped continuous erector spinae plane block
Description: Placebo- Superficially placed (taped to the surface) erector spinae block catheter with a ropivacaine 0.2% infusion at 0.1ml /hr

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Spinal Morphine
Description: 200-300 mcg of spinal morphine

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Spinal Morphine
Description: 200-300 mcg of spinal morphine
Study: NCT06779526

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Heartfulness Meditation
Description: Receiving an orientation session regarding the study, attending once weekly didactic sessions on Zoom for Heartfulness Meditation, and participating in morning and evening meditation for ten to fifteen minutes daily either by themselves or along with the trainer.
Study: NCT06506760

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Immersive Virtual Reality Therapy
Description: 8 sessions of VR therapy over 4 weeks (each of them 20 minutes long).~As a virtual reality source, VRTierOne device (Stolgraf®) were used. Thanks to using head mounted display and the phenomenon of total immersion VR therapy provides an intense visual, auditory and kinesthetic stimulation. It can have a calming and mood-improving effect or help the patients recognize their psychological resources and motivate to the rehabilitation process. In the virtual therapeutic garden there are a rich set of symbols and metaphors based on Ericksonian Psychotherapy approach. The most important is the Garden of Revival which symbolizes the patient's health. It used to be full of life and energy, now it is neglected, requires work to be revived. In the therapeutic process day by day, the therapist tells the patient a symbolic story about his/her situation.
Study: NCT06190132

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Omega 3 fatty acid, gabapentin
Description: To study the effect of omega 3 fatty acids on uremic pruritus in prevalent hemodialysis patients versus the effect of gabapentin

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Omega 3 fatty acid, gabapentin
Description: To study the effect of omega 3 fatty acids on uremic pruritus in prevalent hemodialysis patients versus the effect of gabapentin
Study: NCT05443945

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Nasal Spray
Description: 3 sprays in each nostril 3 times per day

Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: Nasal Spray
Description: 3 sprays in each nostril 3 times per day
Study: NCT05794659

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: AST-201
Description: i.d. (3-week interval, 3 cycles in total)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Paclitaxel
Description: 3-week interval, 6 cycles in total

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Paclitaxel
Description: 3-week interval, 6 cycles in total

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Carboplatin
Description: 3-week interval, 6 cycles in total

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Carboplatin
Description: 3-week interval, 6 cycles in total

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: i.d. (3-week interval, 3 cycles in total)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: rhuGM-CSF(Granulocyte-Macrophage Colony-Stimulating Factor)
Description: i.d. (3-week interval, 3 cycles in total)

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: rhuGM-CSF(Granulocyte-Macrophage Colony-Stimulating Factor)
Description: i.d. (3-week interval, 3 cycles in total)
Study: NCT05842382

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Active Ingredient
Description: IV Vitamin C (12g/day)

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: IV dextrose 5%
Study: NCT05558683

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Randomized clinical trial.
Description: Our study will be a Randomized Clinical Trial. It will be held at the Aymara Abreu Physiotherapy Clinic center, with a maximum duration of 1 year. It will consist of two parts. In the first stage of the treatment we will carry out an initial assessment, and in the second stage a final assessment. After that, the corresponding data analysis will be carried out.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Randomized clinical trial.
Description: Our study will be a Randomized Clinical Trial. It will be held at the Aymara Abreu Physiotherapy Clinic center, with a maximum duration of 1 year. It will consist of two parts. In the first stage of the treatment we will carry out an initial assessment, and in the second stage a final assessment. After that, the corresponding data analysis will be carried out.
Study: NCT04814108

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ZN-c3
Description: ZN-c3 is an investigational drug.
Study: NCT06652360

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Chemical Debridement
Description: The chemical debridement is a dehydrating agent in a gel shape that will dry out the woundbed and biofilm.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Curettage debridement
Description: The use of a currette will clean the wound bed. Debridement by mechanically removing the necrotic tissue and biofilm. This is performed confrom the standard of care standards.
Study: NCT05408091

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TRL345, a human monoclonal antibody
Description: Anti-Human Cytomegalovirus (HCMV) IgG1κ Human Monoclonal Antibody

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TRL345, a human monoclonal antibody
Description: Anti-Human Cytomegalovirus (HCMV) IgG1κ Human Monoclonal Antibody
Study: NCT06452212

Intervention type: OTHER
Intervention: No Intervention
Description: No investigational drug will be administered to participants in this study.
Study: NCT06610994

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: local vibration apply
Description: Local vibration (LV) application will be made with the Vibrasens© (Techno Concept, Mane, France) device. Vibrasens© is a mechanical vibrator that produces transcutaneous vibration stimulations used in sensory-motor rehabilitation. Vibrasens©; It is a non-invasive, therapeutic device. Vibrasens© includes 1 pilot unit, 1 manual vibrator VB200, 4 flat skin contactors for tendon application, 4 round skin contactors for skin application, 1 power supply, 1 user manual and 1 protocol guide. LV application will be applied to the most swollen part of the spastic medial gastrocnemius muscles in the treatment group for 10 minutes. LV will be applied to one of the treatment groups at a frequency of 80Hz with an amplitude of 1 mm.

Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: local vibration apply
Description: Local vibration (LV) application will be made with the Vibrasens© (Techno Concept, Mane, France) device. Vibrasens© is a mechanical vibrator that produces transcutaneous vibration stimulations used in sensory-motor rehabilitation. Vibrasens©; It is a non-invasive, therapeutic device. Vibrasens© includes 1 pilot unit, 1 manual vibrator VB200, 4 flat skin contactors for tendon application, 4 round skin contactors for skin application, 1 power supply, 1 user manual and 1 protocol guide. LV application will be applied to the most swollen part of the spastic medial gastrocnemius muscles in the treatment group for 10 minutes. LV will be applied to one of the treatment groups at a frequency of 80Hz with an amplitude of 1 mm.
Study: NCT06658847

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Night Cream Usage
Description: Participants will use the provided products only on their face and right upper inner arm. The auxiliary cleanser will be used twice per day (morning and evening). The auxiliary sunscreen will be used 15 minutes prior to sun exposure and reapplied after 80 minutes of sweating or swimming. The investigational night cream will be used daily in the evening/at night.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: No Night Cream Usage
Description: Participants will use the provided products only on their face and right upper inner arm. The auxiliary cleanser will be used twice per day (morning and evening). The auxiliary sunscreen will be used 15 minutes prior to sun exposure and reapplied after 80 minutes of sweating or swimming. No night cream will be used.